0.0000 (0.0000%)
  • Bid / Lots
    3.2600/ 1
  • Ask / Lots
    3.5600/ 1
  • Open / Previous Close
    3.3300 / 3.3300
  • Day Range
    Low 3.2200
    High 3.3300
  • 52 Week Range
    Low 2.0600
    High 12.6100
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 3.33
09:32 ET1753.33
10:14 ET1003.3
10:24 ET1003.29
10:26 ET2003.29
10:28 ET1003.29
10:30 ET1003.29
10:42 ET1003.28
10:44 ET1003.28
10:46 ET2003.26
10:48 ET10523.25
10:50 ET2003.275
10:53 ET1003.275
10:55 ET1003.275
11:06 ET2003.3
11:08 ET3953.24
11:09 ET2003.255
11:29 ET1003.29
11:33 ET6003.25
11:36 ET8803.22
11:42 ET1553.2929
11:47 ET1003.3
11:58 ET2003.23
12:00 ET2003.3
12:03 ET1003.3
12:05 ET1003.3
12:14 ET1003.3
12:20 ET1003.3
12:25 ET1003.3
12:36 ET1003.3
12:52 ET1003.3
12:57 ET1003.3
01:21 ET2003.3
01:30 ET21003.3
01:32 ET1003.3
01:42 ET1003.3
01:44 ET2003.3
02:06 ET2003.3
02:11 ET1003.3
02:29 ET1003.3
02:51 ET1003.3
02:54 ET9003.22
02:56 ET1003.26
03:09 ET1003.29
03:21 ET1003.3
03:32 ET1003.3
03:34 ET10553.3
03:36 ET1003.3
03:38 ET5003.26
03:39 ET2003.26
03:41 ET1003.26
03:45 ET1103.2309
03:48 ET2003.26
03:50 ET2003.26
03:52 ET1003.26
03:54 ET1003.26
03:59 ET20023.33
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesACIU
AC Immune SA
United StatesEVLO
Evelo Biosciences Inc
United StatesMLTX
MoonLake Immunotherapeutics
United StatesAADI
Aadi Bioscience Inc
United StatesVAXX
Vaxxinity Inc
United StatesAUTL
Autolus Therapeutics PLC
As of 2022-08-19

Company Information

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

Contact Information

EPFL Innovation Park, Building BLAUSANNE, Switzerland 1015


Independent Chairman of the Board
Douglas Williams
Chief Executive Officer, Co-Founder, Director
Andrea Pfeifer
Chief Financial Officer
Joerg Hornstein
Chief Technical Operations Officer
Piergiorgio Donati
Chief Administrative Officer
Jean-Fabien Monin

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.